IN8bio, Inc. (NASDAQ:INAB) Shares Purchased by Sigma Planning Corp

Sigma Planning Corp lifted its holdings in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 851,280 shares of the company’s stock after acquiring an additional 251,600 shares during the period. Sigma Planning Corp’s holdings in IN8bio were worth $230,000 as of its most recent SEC filing.

IN8bio Price Performance

INAB opened at $0.34 on Monday. IN8bio, Inc. has a twelve month low of $0.22 and a twelve month high of $2.48. The firm has a market cap of $15.69 million, a price-to-earnings ratio of -0.45 and a beta of -0.07. The company has a current ratio of 1.84, a quick ratio of 2.66 and a debt-to-equity ratio of 0.05. The company has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.67.

IN8bio (NASDAQ:INAB) last announced its earnings results on Tuesday, November 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). Equities research analysts expect that IN8bio, Inc. will post -0.56 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reduced their price target on IN8bio from $12.50 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

IN8bio Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.